<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Anesth Pain Med</journal-id><journal-id journal-id-type="iso-abbrev">Anesth Pain Med</journal-id><journal-id journal-id-type="doi">10.5812/aapm</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Anesthesiology and Pain Medicine</journal-title></journal-title-group><issn pub-type="ppub">2228-7523</issn><issn pub-type="epub">2228-7531</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24244921</article-id><article-id pub-id-type="pmc">3821126</article-id><article-id pub-id-type="doi">10.5812/aapm.7790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The Effect of EMLA Cream on Patient-Controlled Analgesia with Remifentanil in ESWL Procedure: A Placebo-Controlled Randomized Study</article-title><alt-title alt-title-type="short">The Effect of EMLA Cream in ESWL Procedure</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Acar</surname><given-names>Arzu</given-names></name><xref ref-type="aff" rid="aff7949">1</xref></contrib><contrib contrib-type="author"><name><surname>Erhan</surname><given-names>Elvan</given-names></name><xref ref-type="aff" rid="aff7949">1</xref></contrib><contrib contrib-type="author"><name><surname>Nuri Deniz</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff7949">1</xref><xref ref-type="corresp" rid="cor7949">*</xref></contrib><contrib contrib-type="author"><name><surname>Ugur</surname><given-names>Gulden</given-names></name><xref ref-type="aff" rid="aff7949">1</xref></contrib></contrib-group><aff id="aff7949"><label>1</label>Department of Anaesthesiology and Reanimation, School of Medicine, Ege University, Izmir, Turkey </aff><author-notes><corresp id="cor7949"><label>*</label>Corresponding author: M. Nuri Deniz, Department of Anaesthesiology and Reanimation, School of Medicine, Ege University, 35100, Izmir, Turkey. Tel.: +90-2323902140, Fax: +90-2323397687, E-mail: <email>mnurideniz@hotmail.com</email>.</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>1</month><year>2013</year></pub-date><pub-date pub-type="ppub"><season>Winter</season><year>2013</year></pub-date><volume>2</volume><issue>3</issue><fpage>119</fpage><lpage>122</lpage><history><date date-type="received"><day>19</day><month>8</month><year>2012</year></date><date date-type="rev-recd"><day>01</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013, Iranian Society of Regional Anesthesia and Pain Medicine</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>To alleviate stinging pain in the skin entry area and visceral discomfort in patients who are undergoing ESWL.</p></sec><sec><title>Objectives</title><p>This study was designed to investigate the effectiveness of the EMLA cream in combination with remifentanil patient-controlled analgesia (PCA) in patients undergoing ESWL treatment.</p></sec><sec><title>Patients and Methods</title><p>Sixty patients were divided into two double-blind randomized groups. Those in the first group were administered 3-5mm of EMLA 5% cream on a marked area; the second group received, as a placebo, a cream with no analgesic effect in the same amount. All patients were administered a remifentanil bolus with a PCA device. Arterial blood pressure, oxygen saturation, and respiratory rate were recorded throughout the procedure; postoperative side effects, agitation, and respiratory depression were measured after. Visual Analogue Scale (VAS) scores were taken preoperatively, perioperatively, directly postoperatively, and 60 minutes subsequent to finishing the procedure.</p></sec><sec><title>Results</title><p>There were no statistically significant differences in the frequency of PCA demands and delivered boluses or among perioperative VAS. No significant side effects were noted. Patient satisfaction was recorded high in both groups.</p></sec><sec><title>Conclusions</title><p>EMLA cream offered no advantage over the placebo cream in patients undergoing ESWL with remifentanil PCA.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Lithotripsy</kwd><kwd>Remifentanil</kwd><kwd>Analgesia, Patient-Controlled</kwd><kwd>EMLA</kwd></kwd-group></article-meta></front><body><sec id="sec2024"><title>1. Background</title><p>Extracorporeal shock wave lithotripsy (ESWL), the most commonly used procedure for the treatment of kidney stones, is painful based on the power of the acoustic shock waves applied (<xref ref-type="bibr" rid="A7790R1">1</xref>). Though believed to be multifactorial, the pathogenesis of the pain during ESWL remains to be elucidated. The cutaneous superficial skin nociceptors and visceral nociceptors such as periosteal, pleural, peritoneal and/or musculoskeletal pain receptors are held responsible for the pain (<xref ref-type="bibr" rid="A7790R2">2</xref>, <xref ref-type="bibr" rid="A7790R3">3</xref>). Other imperative factors include individual differences, the type of lithotripter, site and size of the stones, and pressure of shock waves (<xref ref-type="bibr" rid="A7790R2">2</xref>, <xref ref-type="bibr" rid="A7790R4">4</xref>). During ESWL, general anaesthesia, regional anaesthesia, intravenous anaesthesia or analgesia and sedation can be performed (<xref ref-type="bibr" rid="A7790R5">5</xref>, <xref ref-type="bibr" rid="A7790R6">6</xref>). For this purpose, several studies using opioids such as fentanyl, alfentanil, sufentanil, and remifentanil have been conducted (<xref ref-type="bibr" rid="A7790R7">7</xref>, <xref ref-type="bibr" rid="A7790R8">8</xref>). Since 1986, various studies have been reported on the use of infiltrative or topical local anesthetics for analgesic purposes. The use of local anesthetics during ESWL has been demonstrated to be effective in achieving analgesia (<xref ref-type="bibr" rid="A7790R9">9</xref>, <xref ref-type="bibr" rid="A7790R10">10</xref>).</p></sec><sec id="sec2025"><title>2. Objectives</title><p>The purpose of this double-blind randomized study was to investigate the effects of the combined use of remifentanil used for pain management in patients who planned to undergo ESWL, and the use of EMLA, a topical local anaesthetic.</p></sec><sec id="sec2026"><title>3. Patients and Methods</title><p>After the approval of the Ethics Committee of University Faculty of Medicine and the informed consent of patients, a total of 60 ASA I-II patients with renal stone disease between 18-70 years of age who were scheduled to undergo elective ESWL using the Dornier&#x000ae; lithotripsy (Donier MedTech, Germany) were enrolled in the study. The exclusion criteria were patients with opioid allergy, obesity (BMI &#x0003e; 30), methemoglobinemia, liver disease, alcohol consumption, patients using preoperative opioids and derivatives, cardiovascular and neuropsychiatric medications, pregnant and nursing mothers. No preoperative sedative-hypnotic drugs or antiemetic agents were used. Prior to the ESWL procedure, the data recorded for each patient included age, sex, ASA status, and location and diameter of stones. The patients were double-blindedly randomized into two groups: the first group (group E, n = 30) was administered a total of 10 gr of 5% EMLA cream in the thickness of 3-5 mm on a marked area 10 cm by 15 cm; the second group (group P, n = 30) was administered a cream with no analgesic effect in the same amount and quality as a placebo one hour before the ESWL. Prior to the procedure, each patient was asked to score their level of pain from their kidney stones on a VAS and VRS (Verbal Rating Scale 0-3). Standard monitorization included electrocardiography, heart rate, non-invasive arterial blood pressure, respiratory rate and SpO<sub>2</sub> and all patients were administered O<sub>2</sub> via a facial mask at a rate of 6 liters/min and Remifentanil PCA with a dose of 10 &#x000b5;gr (patient-controlled analgesia, Abbott) (in a bolus of 10 &#x000b5;g, with a lock-out time of 5 minutes) and the patients were asked to press the button when he or she felt pain. During the procedure, vital parameters and VAS and VRS values were recorded for each patient every 10 minutes. Remifentanil administration was discontinued 3 minutes before the termination of the ESWL procedure and PCA demands and deliveries were recorded for each patient. An unpaired t-test was used to compare demographic data and Bonferroni&#x02019;s test to compare the pain scores between the two groups.</p></sec><sec id="sec2027"><title>4. Results</title><p>The results are presented as mean &#x000b1; standard value and a <italic>P</italic> value of &#x0003c; 0.05 was considered statistically significant. Demographic data, duration of ESWL procedure, location of stone, maximum energy and the number of shock waves were similar between the groups (<xref ref-type="table" rid="tbl653">Table 1</xref>). Preoperative, perioperative and postoperative VAS and VRS scores showed similar differences over time (<xref ref-type="fig" rid="fig642">Figures 1</xref> and <xref ref-type="fig" rid="fig643">2</xref>). The remifentanil consumption and the incidence of side effects due to the use of remifentanil were similar between the groups. Both groups had similar number of PCA demands and PCA deliveries (<xref ref-type="table" rid="tbl654">Table 2</xref>).</p><table-wrap id="tbl653" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Demographic Data</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th colspan="2" align="left" valign="middle" rowspan="1">Group E (n = 30)
</th><th align="left" valign="middle" rowspan="1" colspan="1">Group P (n = 30)
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<italic>P</italic> value
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Age, y, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
48.5 &#x000b1; 2.2
</td><td colspan="2" rowspan="1">
43.4 &#x000b1; 2.5
</td><td rowspan="1" colspan="1">
0.13
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Male/Female, No.</bold>
</td><td rowspan="1" colspan="1">
17/13
</td><td colspan="2" rowspan="1">
16/14
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Height, cm, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
165.6 &#x000b1; 1,7
</td><td colspan="2" rowspan="1">
167.9 &#x000b1; 1.6
</td><td rowspan="1" colspan="1">
0.4
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Weight, kg, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
70.7 &#x000b1; 2.1
</td><td colspan="2" rowspan="1">
69.5 &#x000b1; 2.3
</td><td rowspan="1" colspan="1">
0.7
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Duration of The ESWL Procedure, min, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
26.1 &#x000b1; 8.1
</td><td colspan="2" rowspan="1">
30.3 &#x000b1; 8.8
</td><td rowspan="1" colspan="1">
0.06
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Location of Stone:</bold>
</td><td rowspan="1" colspan="1">
&#x000a0;
</td><td colspan="2" rowspan="1">
&#x000a0;
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Renal Pelvic</bold>
</td><td rowspan="1" colspan="1">
9
</td><td colspan="2" rowspan="1">
8
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Upper calyx</bold>
</td><td rowspan="1" colspan="1">
6
</td><td colspan="2" rowspan="1">
8
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Middle calyx</bold>
</td><td rowspan="1" colspan="1">
4
</td><td colspan="2" rowspan="1">
2
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Lower calyx</bold>
</td><td rowspan="1" colspan="1">
8
</td><td colspan="2" rowspan="1">
8
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Ureter</bold>
</td><td rowspan="1" colspan="1">
3
</td><td colspan="2" rowspan="1">
4
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Shock Waves, No.</bold>
</td><td rowspan="1" colspan="1">
1988.3
</td><td colspan="2" rowspan="1">
2000
</td><td rowspan="1" colspan="1">
0.46
</td></tr><tr><td rowspan="1" colspan="1">
<bold>maximum energy, mv</bold>
</td><td rowspan="1" colspan="1">
21.1
</td><td colspan="2" rowspan="1">
21
</td><td rowspan="1" colspan="1">
0.32
</td></tr></tbody></table></table-wrap><fig id="fig642" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>VAS Score Differences Comparing EMLA and Placebo</title></caption><graphic xlink:href="aapm-02-119-i001"/></fig><fig id="fig643" orientation="portrait" position="float"><label>Figure 2.</label><caption><title>VRS Score Differences Comparing EMLA and Placebo</title></caption><graphic xlink:href="aapm-02-119-i002"/></fig><table-wrap id="tbl654" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Data Concerning Remifentanil and PCA, VAS Pain Scores</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">
&#x000a0;
</th><th align="left" valign="middle" rowspan="1" colspan="1">
Group E (n = 30)
</th><th align="left" valign="middle" rowspan="1" colspan="1">
Group P (n = 30)
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<italic>P</italic> value
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Remifentanil dose, &#x000b5;g, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
17.3 &#x000b1; 15.5
</td><td rowspan="1" colspan="1">
21.3 &#x000b1; 12.8
</td><td rowspan="1" colspan="1">
0.29
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Number of PCA demands, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
5.9 &#x000b1; 6.3
</td><td rowspan="1" colspan="1">
5.2 &#x000b1; 8.3
</td><td rowspan="1" colspan="1">
0.79
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Number of PCA deliveries, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
2.1 &#x000b1; 1.5
</td><td rowspan="1" colspan="1">
1.7 &#x000b1; 1.1
</td><td rowspan="1" colspan="1">
0.72
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Preoperative VAS, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
1.2 &#x000b1; 0.8
</td><td rowspan="1" colspan="1">
1.0 &#x000b1; 0
</td><td rowspan="1" colspan="1">
0.16
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Peroperative VAS, Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
3.9 &#x000b1; 0.9
</td><td rowspan="1" colspan="1">
4.1 &#x000b1; 0.4
</td><td rowspan="1" colspan="1">
0.84
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Postoperative VAS (0 min), Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
1.1 &#x000b1; 0.3
</td><td rowspan="1" colspan="1">
1.7 &#x000b1; 1.7
</td><td rowspan="1" colspan="1">
0.72
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Postoperative VAS (60 min), Mean &#x000b1; SD</bold>
</td><td rowspan="1" colspan="1">
1.0 &#x000b1; 0.5
</td><td rowspan="1" colspan="1">
1.0 &#x000b1; 0.0
</td><td rowspan="1" colspan="1">
1.00
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Postoperative Side effects, yes/no</bold>
</td><td rowspan="1" colspan="1">
&#x000a0;
</td><td rowspan="1" colspan="1">
&#x000a0;
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Hypotension</bold>
</td><td rowspan="1" colspan="1">
0/30
</td><td rowspan="1" colspan="1">
0/30
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Respiratory depression</bold>
</td><td rowspan="1" colspan="1">
0/30
</td><td rowspan="1" colspan="1">
0/30
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Nausea and Vomiting</bold>
</td><td rowspan="1" colspan="1">
3/30
</td><td rowspan="1" colspan="1">
3/30
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Dizziness</bold>
</td><td rowspan="1" colspan="1">
3/30
</td><td rowspan="1" colspan="1">
4/30
</td><td rowspan="1" colspan="1">
&#x000a0;
</td></tr></tbody></table><table-wrap-foot><fn id="fn853"><p>Abbreviations: PCA, Patient controlled analgesia; VAS, Visual Analogue Scale.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2028"><title>5. Discussion</title><p>ESWL is a commonly used treatment for patients with kidney and uretheric stones, offering a high efficacy and a low complication rate and is performed on an outpatient basis in most centers. ESWL uses acoustic shock waves to break up kidney stones, during which pain at the entry site of shock waves and deep visceral discomfort is experienced (<xref ref-type="bibr" rid="A7790R11">11</xref>). For this reason, there are numerous studies using opioids (<xref ref-type="bibr" rid="A7790R1">1</xref>, <xref ref-type="bibr" rid="A7790R11">11</xref>, <xref ref-type="bibr" rid="A7790R12">12</xref>). Even though opioids are used extensively because of their high efficiency, their side effects such as bradychardia, hypotension, respiratory depression, sedation, nausea-vomiting, and itching can lengthen their hospital stay which has led clinicians to seek alternatives. Several studies on this issue have attempted to determine various regimens of remifentanil; the optimal bolus dose and infusion rate of remifentanil in itself or compared with other opioids such as sufentanil, alfentanil and fentanyl (<xref ref-type="bibr" rid="A7790R11">11</xref>, <xref ref-type="bibr" rid="A7790R12">12</xref>). These studies compared a remifentanil bolus of 10 &#x000b5;g and remifentanil infusions of 0.05 &#x000b5;g/kg/min and 0.1 &#x000b5;g/kg/min and demonstrated that the administration of bolus combined with low dose infusion had a beneficial analgesic effect and a low incidence of side effects (<xref ref-type="bibr" rid="A7790R12">12</xref>). In this study, we used remifentanil and patient controlled analgesia combined with remifentanil bolus of 10 &#x000b5;g. Since 1986, various studies have been conducted on the use of local anesthetics for analgesic purposes during treatment (<xref ref-type="bibr" rid="A7790R9">9</xref>). Local anesthetics were also shown to be effective in achieving analgesia during ESWL and only 5% of these patients required general anaesthesia (<xref ref-type="bibr" rid="A7790R9">9</xref>). There are a number of studies concerning the use of topical EMLA cream for this purpose (<xref ref-type="bibr" rid="A7790R9">9</xref>, <xref ref-type="bibr" rid="A7790R13">13</xref>). Even though the skin is where the pain is experienced most intensely as a result of the shock waves during the procedure (<xref ref-type="bibr" rid="A7790R6">6</xref>, <xref ref-type="bibr" rid="A7790R14">14</xref>) and EMLA cream is effective in relieving pain, patients usually require additional analgesia since the pain related to ESWL has both cutaneous and visceral components (<xref ref-type="bibr" rid="A7790R2">2</xref>, <xref ref-type="bibr" rid="A7790R3">3</xref>). A study by Bierkens et al. (<xref ref-type="bibr" rid="A7790R15">15</xref>) reported a 23% lower use of fentanyl and lower pain scores compared to placebo, however, the results did not reach statistical significance. Monk et al. (<xref ref-type="bibr" rid="A7790R6">6</xref>) compared EMLA cream with IV fentanyl and reported that even though the application of EMLA cream produced cutaneous analgesia, it failed to produce an opioid-sparing analgesic effect, and was not superior to placebo. They also reported that EMLA cream produced no decrease in postoperative side effects and recovery times. In conclusion, considering EMLA&#x02019;s slow onset, the inability to identify the precise entrance site for the shock waves and the high cost of the drug, the routine use of EMLA was not recommended by the authors (<xref ref-type="bibr" rid="A7790R6">6</xref>). Barcena et al. (<xref ref-type="bibr" rid="A7790R16">16</xref>) conducted a study on 20 patients who had been unable to tolerate pain without IV analgesia during ESWL. In this study, 10 gr of EMLA cream was applied on the skin over the area of 64-100 cm <sup>2</sup> 60 minutes before the second session. Despite higher voltages, lower pain scores were found in patients for whom EMLA cream was used and only two patients required further analgesia. In addition, all patients required additional fentanyl in the first session without EMLA. In a study by Ganapathy et al (<xref ref-type="bibr" rid="A7790R17">17</xref>), one group received 30 gr EMLA cream and the other group received a placebo 60-90 minutes before the procedure. All patients received 5 mcg/kg of alfentanil via a PCA machine with a lockout time of 3 minutes and no significant differences were noted in pain scores, side effects and duration of stay in the post anaesthesia care unit between EMLA cream and placebo. In a double-blind randomized controlled study of 60 ASA I-III patients between 18-70 years of age, aiming at investigating the effect of EMLA cream in lithotripsy by Terri et al. (<xref ref-type="bibr" rid="A7790R6">6</xref>), one group received 30 gr of EMLA cream applied to a 15x20 cm area of skin 90 minutes prior the procedure and the other group received placebo with the same appearance and consistency and patients with pain received an additional bolus of alfentanil 5 &#x000b5;g/kg and an infusion of 0.5 &#x000b5;g/kg/min. The dose of alfentanil was doubled in those patients with continuing pain. They also reported that there was no change in pain scores at energy levels of 10,12,15 mV but there was a significant decrease in pain at energy levels of 18 and 20 mV in the EMLA group. However, no significant differences were noted in alfentanil use between the two groups. In the present study, similar to those of Ganapathy and Terri (<xref ref-type="bibr" rid="A7790R6">6</xref>, <xref ref-type="bibr" rid="A7790R17">17</xref>), 10 gr of EMLA cream was applied to a 10x15 cm area of skin 1 hour before the procedure. Both authors preferred alfentanil as the opioid. In this study, we preferred remifentanil, which has a short duration. We administered remifentanil at a bolus dose of 10 &#x000b5;g with a lockout time of 5 minutes. As in the study by Ganapathy et al., no basal infusion was administered. Thus, keeping the dose of remifentanil at the lowest tolerable level, we tried to assess how effective EMLA cream was. In this application, no hypotension or respiratory depression due to remifentanil was observed. Side effects such as nausea-vomiting and dizziness were similarly low in both groups. No patients had severe pain necessitating the administration of other analgesics or the termination of the procedure. Even though it has been suggested that topical anesthetics used for the elimination of cutaneous component of pain can provide a more comfortable analgesia by reducing the use of opioids and their side effects, we demonstrated in this study that EMLA cream did not lead to a decrease in the dose of remifentanil compared to a placebo during ESWL. In conclusion, we found that EMLA cream combined with PCA using remifentanil was not significantly superior to a placebo in ESWL and did not lead to a decrease in the dose of remifentanil used during ESWL. However, there are different application schemes for EMLA. We do consider that the investigation of the use of EMLA cream alone or combined with other IV analgesia regimens will be able to give further insight into the efficacy of EMLA cream.</p></sec></body><back><ack><p>None declared.</p></ack><fn-group><fn id="afn1907" fn-type="other"><p><bold>Implication for health policy/practice/research/medical education:</bold> Several drugs and methods are being evaluated for aimed at pain control for renal stones during ESWL. This study investigates the effect of EMLA cream on patient-controlled analgesia with remifentanil during the ESWL procedure.</p></fn><fn id="afn1908" fn-type="other"><p><bold>Please cite this paper as:</bold> Acar A, Erhan E, Nuri Deniz M, Ugur G. The Effect of EMLA Cream on Patient-Controlled Analgesia with Remifentanil in ESWL Procedure: A Placebo-Controlled Randomized Study. Anesth Pain. 2013;2(3):119-22. DOI: 10.5812/aapm.7790</p></fn><fn id="afn1909" fn-type="other"><p><bold>Authors&#x02019; Contribution:</bold> Arzu Acar; Study design, Conduct of the study, Data collection, Data analysis and Manuscript preparation. MNuri Deniz; Data collection, Data analysis and Manuscript preparation. Elvan Erhan; Study design, Data collection, Data analysis and Manuscript preparation. Gulden Ugur; Data analysis and Manuscript preparation.</p></fn><fn id="afn1910" fn-type="financial-disclosure"><p><bold>Financial Disclosure:</bold> None declared.</p></fn><fn id="afn7764" fn-type="abbr"><p><bold>Funding/Support:</bold> None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="A7790R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burmeister</surname><given-names>MA</given-names></name><name><surname>Brauer</surname><given-names>P</given-names></name><name><surname>Wintruff</surname><given-names>M</given-names></name><name><surname>Graefen</surname><given-names>M</given-names></name><name><surname>Blanc</surname><given-names>I</given-names></name><name><surname>Standl</surname><given-names>TG</given-names></name></person-group><article-title>A comparison of anaesthetic techniques for shock wave lithotripsy: the use of a remifentanil infusion alone compared to intermittent fentanyl boluses combined with a low dose propofol infusion.</article-title><source>Anaesthesia.</source><year>2002</year><volume>57</volume><issue>9</issue><fpage>877</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2044.2002.02820.x</pub-id><pub-id pub-id-type="pmid">12190752</pub-id></element-citation></ref><ref id="A7790R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>NP</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Analgesia for pain control during extracorporeal shock wave lithotripsy: Current status.</article-title><source>Indian J Urol.</source><year>2008</year><volume>24</volume><issue>2</issue><fpage>155</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4103/0970-1591.40607</pub-id><pub-id pub-id-type="pmid">19468389</pub-id></element-citation></ref><ref id="A7790R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Koehrmann</surname><given-names>KU</given-names></name><name><surname>Denig</surname><given-names>N</given-names></name><name><surname>Michel</surname><given-names>MS</given-names></name><name><surname>Alken</surname><given-names>P</given-names></name></person-group><article-title>What are the parameters for predictive selection of patients requiring anesthesia for extracorporeal shockwave lithotripsy?</article-title><source>Eur Urol.</source><year>1998</year><volume>34</volume><issue>2</issue><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1159/000019690</pub-id><pub-id pub-id-type="pmid">9693241</pub-id></element-citation></ref><ref id="A7790R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basar</surname><given-names>H</given-names></name><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>Ozcan</surname><given-names>S</given-names></name><name><surname>Buyukkocak</surname><given-names>U</given-names></name><name><surname>Sari</surname><given-names>F</given-names></name><name><surname>Apan</surname><given-names>A</given-names></name><etal>et al.</etal></person-group><article-title>Four analgesic techniques for shockwave lithotripsy: eutectic mixture local anesthetic is a good alternative.</article-title><source>J Endourol.</source><year>2003</year><volume>17</volume><issue>1</issue><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1089/089277903321196706</pub-id><pub-id pub-id-type="pmid">12639353</pub-id></element-citation></ref><ref id="A7790R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monk</surname><given-names>TG</given-names></name><name><surname>Boure</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>PF</given-names></name><name><surname>Meretyk</surname><given-names>S</given-names></name><name><surname>Clayman</surname><given-names>RV</given-names></name></person-group><article-title>Comparison of intravenous sedative-analgesic techniques for outpatient immersion lithotripsy.</article-title><source>Anesth Analg.</source><year>1991</year><volume>72</volume><issue>5</issue><fpage>616</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1213/00000539-199105000-00008</pub-id><pub-id pub-id-type="pmid">2018218</pub-id></element-citation></ref><ref id="A7790R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monk</surname><given-names>TG</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>White</surname><given-names>PF</given-names></name><name><surname>Albala</surname><given-names>DM</given-names></name><name><surname>Clayman</surname><given-names>RV</given-names></name></person-group><article-title>Effect of topical eutectic mixture of local anesthetics on pain response and analgesic requirement during lithotripsy procedures.</article-title><source>Anesth Analg.</source><year>1994</year><volume>79</volume><issue>3</issue><fpage>506</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1213/00000539-199409000-00018</pub-id><pub-id pub-id-type="pmid">8067556</pub-id></element-citation></ref><ref id="A7790R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coloma</surname><given-names>M</given-names></name><name><surname>Chiu</surname><given-names>JW</given-names></name><name><surname>White</surname><given-names>PF</given-names></name><name><surname>Tongier</surname><given-names>WK</given-names></name><name><surname>Duffy</surname><given-names>LL</given-names></name><name><surname>Armbruster</surname><given-names>SC</given-names></name></person-group><article-title>Fast-tracking after immersion lithotripsy: general anesthesia versus monitored anesthesia care.</article-title><source>Anesth Analg.</source><year>2000</year><volume>91</volume><issue>1</issue><fpage>92</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1213/00000539-200007000-00018</pub-id><pub-id pub-id-type="pmid">10866893</pub-id></element-citation></ref><ref id="A7790R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosow</surname><given-names>C</given-names></name></person-group><article-title>Remifentanil: a unique opioid analgesic.</article-title><source>Anesthesiology.</source><year>1993</year><volume>79</volume><issue>5</issue><fpage>875</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/00000542-199311000-00002</pub-id><pub-id pub-id-type="pmid">7902031</pub-id></element-citation></ref><ref id="A7790R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aeikens</surname><given-names>B</given-names></name><name><surname>Fritz</surname><given-names>KW</given-names></name><name><surname>Hoehne</surname><given-names>E</given-names></name></person-group><article-title>Initial experience with local anesthesia in extracorporeal shock wave lithotripsy.</article-title><source>Urol Int.</source><year>1986</year><volume>41</volume><issue>4</issue><fpage>246</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000281210</pub-id><pub-id pub-id-type="pmid">3787844</pub-id></element-citation></ref><ref id="A7790R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demir</surname><given-names>E</given-names></name><name><surname>Kilciler</surname><given-names>M</given-names></name><name><surname>Bedir</surname><given-names>S</given-names></name><name><surname>Erten</surname><given-names>K</given-names></name><name><surname>Ozgok</surname><given-names>Y</given-names></name></person-group><article-title>Comparing two local anesthesia techniques for extracorporeal shock wave lithotripsy.</article-title><source>Urology.</source><year>2007</year><volume>69</volume><issue>4</issue><fpage>625</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2007.01.003</pub-id><pub-id pub-id-type="pmid">17445637</pub-id></element-citation></ref><ref id="A7790R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beloeil</surname><given-names>H</given-names></name><name><surname>Corsia</surname><given-names>G</given-names></name><name><surname>Coriat</surname><given-names>P</given-names></name><name><surname>Riou</surname><given-names>B</given-names></name></person-group><article-title>Remifentanil compared with sufentanil during extra-corporeal shock wave lithotripsy with spontaneous ventilation: a double-blind, randomized study.</article-title><source>Br J Anaesth.</source><year>2002</year><volume>89</volume><issue>4</issue><fpage>567</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/bja/aef202</pub-id><pub-id pub-id-type="pmid">12393357</pub-id></element-citation></ref><ref id="A7790R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>HJ</given-names></name><name><surname>Galvin</surname><given-names>EM</given-names></name><name><surname>Dirckx</surname><given-names>M</given-names></name><name><surname>Banwarie</surname><given-names>P</given-names></name><name><surname>Ubben</surname><given-names>JF</given-names></name><name><surname>Zijlstra</surname><given-names>FJ</given-names></name><etal>et al.</etal></person-group><article-title>Remifentanil as a single drug for extracorporeal shock wave lithotripsy: a comparison of infusion doses in terms of analgesic potency and side effects.</article-title><source>Anesth Analg.</source><year>2005</year><volume>101</volume><issue>2</issue><fpage>365</fpage><lpage>70,</lpage><comment>table of contents</comment><pub-id pub-id-type="pmid">16037145</pub-id></element-citation></ref><ref id="A7790R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiselius</surname><given-names>HG</given-names></name></person-group><article-title>Cutaneous anesthesia with lidocaine-prilocaine cream: a useful adjunct during shock wave lithotripsy with analgesic sedation.</article-title><source>J Urol.</source><year>1993</year><volume>149</volume><issue>1</issue><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8417220</pub-id></element-citation></ref><ref id="A7790R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>V</given-names></name><name><surname>Long</surname><given-names>CW</given-names></name><name><surname>Meister</surname><given-names>MJ</given-names></name></person-group><article-title>Intercostal blocks with local infiltration anesthesia for extracorporeal shock wave lithotripsy.</article-title><source>Anesth Analg.</source><year>1987</year><volume>66</volume><issue>1</issue><fpage>85</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1213/00000539-198701000-00015</pub-id><pub-id pub-id-type="pmid">3541689</pub-id></element-citation></ref><ref id="A7790R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bierkens</surname><given-names>AF</given-names></name><name><surname>Maes</surname><given-names>RM</given-names></name><name><surname>Hendrikx</surname><given-names>JM</given-names></name><name><surname>Erdos</surname><given-names>AF</given-names></name><name><surname>de Vries</surname><given-names>JD</given-names></name><name><surname>Debruyne</surname><given-names>FM</given-names></name></person-group><article-title>The use of local anesthesia in second generation extracorporeal shock wave lithotripsy: eutectic mixture of local anesthetics.</article-title><source>J Urol.</source><year>1991</year><volume>146</volume><issue>2</issue><fpage>287</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1856917</pub-id></element-citation></ref><ref id="A7790R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barcena</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Gude</surname><given-names>F</given-names></name><name><surname>Vidal</surname><given-names>MI</given-names></name><name><surname>Fernandez</surname><given-names>S</given-names></name></person-group><article-title>EMLA cream for renal extracorporeal shock wave lithotripsy in ambulatory patients.</article-title><source>Eur J Anaesthesiol.</source><year>1996</year><volume>13</volume><issue>4</issue><fpage>373</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/00003643-199607000-00012</pub-id><pub-id pub-id-type="pmid">8842659</pub-id></element-citation></ref><ref id="A7790R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganapathy</surname><given-names>S</given-names></name><name><surname>Razvi</surname><given-names>H</given-names></name><name><surname>Moote</surname><given-names>C</given-names></name><name><surname>Parkin</surname><given-names>J</given-names></name><name><surname>Yee</surname><given-names>I</given-names></name><name><surname>Gverzdys</surname><given-names>S</given-names></name><etal>et al.</etal></person-group><article-title>Eutectic mixture of local anaesthetics is not effective for extracorporeal shock wave lithotripsy.</article-title><source>Can J Anaesth.</source><year>1996</year><volume>43</volume><issue>10</issue><fpage>1030</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1007/BF03011905</pub-id><pub-id pub-id-type="pmid">8896855</pub-id></element-citation></ref></ref-list></back></article>